Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension: A Randomized Controlled Study

NCT07932145 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07932145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension: A Randomized Controlled Study
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Phase 4
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
April 30, 2028
Enrollment
128 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension (htn), low-renin essential hypertension

Arms

As registered; 2 arms.

  • Early Eplerenone-Based Treatment ExperimentalEplerenone

    Participants will receive stepped antihypertensive treatment starting with eplerenone 50 mg orally once daily. Treatment will be intensified as needed by sequentially adding amlodipine 5 mg once daily, increasing eplerenone to 50 mg twice daily, increasing amlodipine to 5 mg twice daily, adding hydrochlorothiazide 12.5 mg once daily, adding doxazosin 4 mg once daily, and increasing hydrochlorothiazide to 25 mg once daily. Participants taking two antihypertensive drugs before washout will generally start with eplerenone plus amlodipine. Treatment adjustments will depend on blood pressure, tolerability, and safety assessments, with a target seated office blood pressure below 140/90 mmHg. Treatment will continue for 24 weeks.

  • Standard Treatment Active comparatorTelmisartan

    Participants will receive stepped antihypertensive treatment starting with telmisartan 40 mg orally once daily. Treatment will be intensified as needed by sequentially adding amlodipine 5 mg once daily, increasing telmisartan to 80 mg once daily, increasing amlodipine to 5 mg twice daily, adding hydrochlorothiazide 12.5 mg once daily, adding doxazosin 4 mg once daily, and increasing hydrochlorothiazide to 25 mg once daily. Participants taking two antihypertensive drugs before washout will generally start with telmisartan plus amlodipine. Treatment adjustments will depend on blood pressure, tolerability, and safety assessments, with a target seated office blood pressure below 140/90 mmHg. Treatment will continue for 24 weeks.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure at Week 12 Baseline and Week 12

    Change in mean daytime systolic blood pressure, measured in mmHg by 24-hour ambulatory blood pressure monitoring, from baseline to Week 12. Mean daytime systolic blood pressure is the average of all valid daytime systolic readings. A valid recording requires at least 70% of scheduled readings, including at least 20 daytime readings and 7 nighttime readings. Change is calculated as the Week 12 value minus the baseline value; a negative value indicates a reduction in blood pressure.

Lead sponsor's other trials

China National Center for Cardiovascular Diseases, most recent start first.

Similar trials

Same condition (Hypertension) and phase, most recent start first.